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Abstract 
 
Topoisomerase II (Top2) activity involves an 
intermediate in which the topoisomerase is 
covalently bound to a DNA double-strand 
break (DSB) via a 5’-phosphotyrosyl bond. 
Whilst these intermediates are normally 
transient they can be stabilized by anti-
tumour agents that act as Top2 ‘poisons’, 
resulting in the induction of cytotoxic DSBs, 
and they are implicated in the formation of 
site-specific translocations that are commonly 
associated with cancer. Recently, we revealed 
that TRAF and TNF Receptor Associated 
protein (TTRAP) is a 5’-tyrosyl DNA 
phosphodiesterase (5’-TDP) that can cleave 
5’-phosphotyrosyl bonds, and denoted this 
protein tyrosyl DNA phsphodiesterase-2 
(TDP2). Here, we have generated TDP2-
deleted DT40 cells and we show that TDP2 is 
the major if not only 5’-TDP activity present 
in vertebrate cells. We also show that TDP2-
deleted DT40 cells are highly sensitive to the 
anticancer Top2 ‘poison’, etoposide, but are 
not hypersensitive to the Top1 poison 
camptothecin or the DNA alkyating agent 
methyl methanesulphonate. These data 
identify an important mechanism for 
resistance to Top2-induced chromosome 
breakage and raise the possibility that TDP2 
is a significant etiological factor in cancer 
development and treatment.  
 
Introduction 
 
Topoisomerases release torsional stress in DNA 
and decatenate chromosomes during mitosis 
(1,2). A key intermediate of topoisomerase 
activity is the cleavage complex, within which 
the topoisomerase cleaves one or both strands of 
DNA and becomes covalently linked to the 3’- 
or 5’-terminus of the break via a phosphotyrosyl 
bond. The cleavage complex is normally 
transient, since the topoisomerase reseals the 
break at the end of its catalytic cycle. However, 
cleavage complexes are the targets of a class of 
anti-tumour agents that act as toposiomerase 
‘poisons’, prolonging the half-life of the cleaved 
intermediate and resulting in the formation of 
potentially cytotoxic DNA strand breaks (3). 
Whereas topoisomerase I  (Top1) poisons induce 
DNA breaks in which the topoisomerase is 
linked via a phosphotyrosyl bond to the 3’-
terminus of the break, topoisomerase II (Top2) 
poisons induce DNA strand breaks in which the 
topoisomerase is linked via a phosphotyrosyl 
bond to the 5’-terminus. Top2 associated DNA 
breaks account not only for the clinical efficacy 
of Top2 poisons as anti-tumour cytotoxic drugs, 
but are also implicated in genome instability, 
chromosome translocations, and carcinogenesis 
(4,5). Recently, we identified a human 5’-tyrosyl 
DNA phosphodiesterase (5’-TDP) activity that 
can cleave 5’-phosphotyrosyl bonds and might 
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thereby release trapped topoisomerase from 5’-
termini (6). This enzyme, previously known as 
TTRAP, is a member of the metal-dependent 
super-family of phosphodiesterases and has been 
implicated in NF-kappaB signalling (7,8), ETS1-
mediated transcriptional regulation (9), apoptotic 
regulation (10), and left-right axis determination 
during development in zebrafish (11). Based on 
its TDP activity we denoted TTRAP as tyrosyl 
DNA phopshodiesterase 2 (TDP2) and 
speculated that this enzyme might play an 
important role in the repair of Top2-associated 
DSBs induced by Top2 poisons (6). We now 
demonstrate using avian DT40 cells that TDP2 is 
the primary if not the only 5’-TDP activity in 
vertebrate cells, and that genetic deletion of 
TDP2 results in specific and severe sensitivity to 
Top2 poisons. These data identify TDP2 as a 
novel cellular component of the DNA repair 
pathway/s that protect cells from topoisomerase 
induced chromosomal breakage and suggest that 
TDP2 may be a useful clinical target for 
inhibition during the chemotherapeutic 
application of anticancer Top2 poisons.  
 
Experimental Procedures 
 
5’-tyrosyl DNA phosphodiesterase activity  
 
The 19-mer and 20-mer DSB substrates were 
prepared as described previously (Cortes 
Ledesma et al. 2009). Briefly, the 5′ -Y-18-bp 
(5′-Y-TCCGTTGAAGCCTGCTTT-3′) was 
annealed with 19bp (5′ -
GAAAGCAGGCTTCAACGGA-3′) or 20-bp 
(5′-AGAAAGCAGGCTTCAACGGA-3′) 
oligonucleotides, respectively, and the resulting 
1-bp or 2-bp 5′ -overhang filled using Klenow 
DNA polymerase in the presence of [α-32P]-
dCTP (for the 19-mer) or both [α-32P]-dCTP and 
ddTTP (for the 20-mer). Inclusion of the latter 
for the 20-mer inhibits degradation of the 
substrate by nonspecific 3’-nucleases present in 
whole cell extract. For single-stranded and 
nicked duplex substrates, the single-stranded 32P-
labelled 5’-Y-19mer prepared as above was gel 
purified from denaturing gels and either 
employed alone (single-stranded substrate) or 
annealed, along with the 21-bp oligonucleotide 
(5’-GCGCAGCTAGCGGCGGATGGC-3’), to 
the 40-bp oligonucleotide (5’-
GAAAGCAGGCTTCAACGGAGCCATCCGC
CGCTAGCTGCGC-3’). Reactions were carried 
out by incubating the indicated substrate (50 
nM) with whole-cell protein extract (250 ng/ml) 
or the indicated concentration of recombinant 
human His-TDP2/TTRAP protein, which was 
expressed in E.coli and prepared as described 
previously (6), in 25 mM HEPES pH8.0, 130 
mM KCl, 10 mM MgCl2, 1 mM DTT and in the 
presence or absence of orthovanadate, BSA, or 
phosphotyrosine-BSA (Sigma) as indicated at 
37°C for 60min. In reactions containing cell 
extract 50 mM competitor single-stranded 
oligonucleotide (5′ -
CTAACTTGAGCGAAACGGT-3′) was also 
included to further reduce nonspecific 
nucleolytic degradation of the duplex substrate. 
To examine whether the product of hTDP2 
activity was a ligatable 5’-terminus, nicked 
duplex substrate described above was incubated 
with hTDP2 and/or human DNA ligase III, 
which was expressed in E.coli and purified as 
described previously (12,13). All reactions were 
terminated by the addition of formamide loading 
buffer and fractionated by denaturing PAGE; 
images were analysed by phosphorimaging. 
 
Cell cycle analysis 
 
Cells grown for the indicated time in the 
presence or absence of 40 nM etoposide were 
fixed for 24h in 70% ethanol at -20oC. Cells 
were then washed twice in PBS-3% BSA, 
resuspended in PBS containing 10 mg/ml 
propidium iodide and 100mg/ml RNAse A and 
analysed using a FACS Canto device (Becton 
Dickinson).  
 
Cell Culture and Transfection  
 
Chicken DT40 B-lymphoma cells were cultured 
in RPMI-1640 medium supplemented with 10−5 
M β-mercaptoethanol, penicillin, streptomycin, 
10% fetal calf serum (FCS), and 1% chicken 
serum (Sigma, St Louis, MO, USA) at 39°C.   
 
Generation of TDP2 mutant DT40 cells 
 
To generate TDP2 gene disruption constructs, 
TDP2 sequences were amplified by PCR from 
genomic DNA from DT40 cells (Clone 18) using 
the primer combinations 5′- CCCAAGCTT 
GGAAAGTACTGTGCTCCGAGT-3′ and 5′- 
CGCGGATCC 
GCCCATCAATGTTCCAAGTTAT-3′ for the 
5’ arm, and 5′-CGCGGATCC 
GGATGAGCATGGACAATGAATA-3′ and 5′- 
CCGCTCGAG 
GCGCTGTAGGTAGAACAGAAGC-3′ for the 
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3’ arm. The amplified PCR products were 
cloned into the pCR2.1-TOPO vector 
(Invitrogen, CA, USA) and confirmed by 
Sequencing.  2.5-kb HindIII/BamHI (left arm) 
and 4.4-Kb BamHI/XhoI (right arm) DNA 
fragments were then ligated into pCR2.1-TOPO 
vector. A single drug-resistance gene (Puro, 
hisD, or bsr) was then inserted into the BamHI 
site of the pCR2.1 vector between the TDP2 
targeting sequences. To generate TDP2-/−/− cells, 
2×107 cells were electroporated (BioRad) with 
30 μg of the relevant linearized (with XhoI) 
TDP2 gene-disruption construct and drug-
resistant colonies selected by incubation in 
medium containing 0.5 μg/ml puromycin 
dihydrochloride (Sigma-Aldrich), 1.0 mg/ml D-
histidinol dihydrochloride (Sigma-Aldrich), or 
25µg/ml blasticidine S hydrochloride (Sigma-
Aldrich), alone or in combination as appropriate. 
To detect successful targeting of TDP2 alleles, 
genomic DNA was isolated from multiple drug-
resistant clones, digested with Xhol I and 
EcoRV, and subjected to Southern blot analysis 
using a 0.8 Kb probe (N-probe) amplified using 
the primers 5′-
TGAAGCAAAGCTGACAAGCTGC-3′ and 5′-
CCAGTTAGCGGCAACATTTGAG-3′. 
Following three consecutive rounds of gene 
targeting with constructs encoding resistance to 
Puro, HisD, and Bsr, respectively, two TDP2-/-/- 
clones (clone 8 and clone 93) were recovered. 
These clones were employed for phenotypic 
analysis along with parental DT40 cells and a 
single TDP2-/-/+ clone (clone H13) in which only 
two of the three TDP2 alleles were targeted.   
 
Generation of hTDP2-KO and hTDP2 
catalytic mutant-KO cells 
 
pcDNA3.1-HisC (Invitrogen) constructs 
expressing wild-type human TDP2 and 
TDP2D262A were described previously [note that 
TDP2 was previously denoted TTRAP (6)].   
TDP2-/-/- DT40 cells were electroporated with 
pcDNA3.1-HisC –TDP2, pcDNA3.1-HisC-
TDP2 (D262A) or pcDNA3.1-HisC empty 
vector.  After selection in 1.5 mg/ml G418 
(Gibco, Invitrogen) for 6 days, pooled 
populations of transfectants were collected. For 
western blotting, cell extracts were prepared in 
RIPA buffer [(150 mM NaCl, 1% NP-40, 0.5% 
Na deoxycholate, 0.1% SDS, 50 mM Tris-Cl, 
pH 8.0, 1 mM PMSF, and complete protease 
inhibitor cocktail (Roche)),  resolved by SDS-
PAGE, and blotted onto nitrocellulose 
membranes (GE Healthcare).  Membranes were 
blocked for 1hr in PBS-Tween 20 (PBST) 
containing 5% non-fat dried milk (NFDM) and 
then incubated for 2h with affinity-purified anti-
TDP2 polyclonal antibody (SY1340)(6) at a 
1/200 dilution, in PBST plus 5% NFDM. 
Membranes were rinsed in PBST and incubated 
in PBST plus 5% NFDM containing 
horseradish-peroxidase-conjugated anti-rabbit 
IgG (DAKO), as appropriate, at a 1/3,000 
dilution for 1h at room temperature. Membranes 
were then rinsed with PBST and antibody 
complexes detected by enhanced 
chemiluminescence (GE Healthcare).  
 
Clonogenic Survival Assays.  
 
To determine sensitivity, cells were plated in 5 
ml medium containing 1.5% (by weight) 
methylcellulose (Sigma-Aldrich) in 6-well plates 
at 50, 500, and 5000 cells per well per treatment 
condition. Media also contained the indicated 
concentration of methyl methanesulphonate 
(MMS), camptothecin (CPT), or etoposide (VP-
16). In all experiments, cells were incubated for 
7–11 days and visible colonies counted. The 
surviving fraction was calculated by dividing the 
average number of visible colonies in treated 
wells by the average number of colonies in 
untreated wells. 
 
Results 
 
TDP2 (also known as TTRAP) is the first human 
enzyme with 5’-tyrosyl DNA phosphodiesterase 
(5’-TDP) activity to be identified (6). To 
characterise this enzyme further we examined its 
sensitivity to vanadate and its DNA substrate 
specificity.  The 5’-TDP activity of histidine-
tagged TDP2 (His-TDP2) on oligonucleotide 
duplexes harbouring 5’-phosphotyrosyl termini 
was inhibited by vanadate (Fig.1A). This is 
similar to the 3’-TDP activity of TDP1, and 
suggests the involvement of a phosphate 
transition-state during the 5’-TDP reaction. To 
examine the specificity of His-TDP2 for nucleic 
acid substrates we first examined whether this 
activity was inhibited by BSA-tyrosine 
phosphate (BSA-TP), a derivative of BSA 
containing a phosphotyrosine bond similar to 
that present in the oligonucleotide 5’-
phosphotyrosyl substrate.  BSA-TP failed to 
inhibit the activity of His-TDP2, even if present 
at 60-fold higher concentrations than the 
oligonucleotide 5’-phosphotyrosyl substrate, 
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suggesting that His-TDP2 activity was specific 
for nucleic acid substrates (Fig.1B).  His-TDP2 
was active on a phosphotyrosyl bond present at 
the 5’-terminus of either a single-stranded 
oligonucleotide, a double-strand break (DSB), or 
a single-strand break (SSB), but was most active 
on the DSB substrate (Fig.1C). This is consistent 
with a role for TDP2 in the repair of Top2-
associated DSBs.  However, the activity of His-
TDP2 on SSBs with 5’-phosphotyrosyl termini 
may also be relevant, since Top2 also induces 
this type of break (4).  We have suggested that 
the product of TDP2 activity is a 5’-phosphate 
terminus that is competent for DNA ligation, 
based on the sensitivity of the TDP2 product to 
calf intestinal phosphatase (6). This is an 
important possibility, because if true it would 
provide an error-free mechanism for repairing 
topoisomerase-associated DNA breaks by simple 
DNA ligation.  We therefore addressed whether 
the termini created by TDP2 are ligatable, 
directly, by employing a substrate that contained 
a 5’-phosphotyrosyl terminus within the context 
of a single-stranded nick. Indeed, incubation of 
this substrate with His-TDP2 and DNA ligase, 
but not with either His-TDP2 or DNA ligase 
alone, resulted in conversion of the radiolabeled 
19-mer containing the phosphotyrosyl terminus 
into a radiolabeled 40-mer, confirming that the 
His-TDP2 generates a ligatable 5’-phosphate 
terminus (Fig.1D).   
To examine directly the importance of 
TDP2 for the repair and cellular resistance to 
Top2 associated DNA breaks we disrupted each 
of the three TDP2 alleles in chicken DT40 cells, 
thereby creating a TDP2-deleted mutant cell line 
(Supplementary Fig.1).  The doubling time of 
TDP2-/-/- cells was not significantly different 
from that of wild-type DT40 cells, suggesting 
that cells proliferate at normal rates in the 
absence of TDP2 (Fig.2A).  TDP2 is currently 
the only 5’-TDP activity identified in human 
cells. To address whether other such activities 
might be present, we compared whole cell 
extracts from TDP2+/+/+, TDP2-/-/+, and TDP2-/-/- 
cells for levels of 5’-TDP activity. Whereas 
whole cell extracts prepared from wild type 
TDP2+/+/+ cells readily converted 5’-
phosphotyrosyl termini to 5’-phosphate termini 
at a DSB, whole cell extracts from TDP2-/-/- cells 
failed to do so (Fig.2B & 2C). We noted that cell 
extract from TDP2-/-/+ cells exhibited 
intermediate levels of 5’-TDP activity, 
suggesting that a single wild-type TDP2 allele is 
sufficient to provide detectable levels of 5’-TDP 
activity (Fig.2B). Similar observations were 
observed for 5’-phosphotyrosyl termini present 
at SSBs (Fig.2D). Stable expression of wild-type 
human TDP2 in TDP2-/-/- cells (TDP2-/-/- hTDP2 
cells) restored 5’-TDP activity, whereas stable 
expression of human TDP2D262A in TDP2-/-/- cells 
(TDP2-/-/- hTDP2 D262A cells) harbouring a mutated 
active site did not, confirming that the absence 
of 5’-TDP activity in TDP2-/-/- cells was the 
result of TDP2 deletion (Fig.2E). Taken together 
these data suggest that TDP2 is the major if not 
the only 5’-TDP activity present in DT40 cell 
extracts.  
Top2 poisons are an important class of 
anti-tumour agents that exert their clinical 
efficacy by inducing Top2-associated DSBs 
(14). Based on the 5’-TDP activity of TDP2, we 
proposed that this enzyme might be important 
for cellular resistance to Top2 poisons (6). To 
test this hypothesis we compared the sensitivity 
of TDP2+/+/+, TDP2-/-/+, and TDP2-/-/- cells to 
etoposide, a Top2 poison employed in the 
treatment of lung, ovarian, and testicular cancer. 
Flow cytometry revealed that cell cycle 
progression slowed in both TDP2+/+/+ cells 
TDP2-/-/- cells within 24hr of addition of 40nM 
etoposide to the culture medium (Fig.3). 
However, whereas the cell cycle profile in 
TDP2+/+/+ cells returned to near-normal within 
48 hr, a significant fraction of TDP2-/-/- cells 
(~24%) accumulated in a sub-G1 peak, 
indicative of cell death (Fig.3, bottom panels). 
To confirm the hypersensitivity of TDP2-/-/- cells 
to etoposide we next employed clonogenic 
survival assays. Strikingly, both of the two 
independent TDP2-/-/- cell clones generated by 
gene targeting exhibited high sensitivity to 
etoposide, with three-to-four log-cell kill 
observed in TDP2-/-/- cells at etoposide 
concentrations that were largely non-toxic to 
TDP2+/+/+ or TDP2-/-/+ cells (Fig.4A & 4B). 
Importantly, TDP2-/-/- hTDP2 cells expressing 
human TDP2 exhibited levels of etoposide 
sensitivity similar to TDP2+/+/+cells, confirming 
that the sensitivity of TDP2-/-/- cells was due to 
loss of TDP2 protein (Fig.4C). Moreover, TDP2-
/-/- hTDP2 D262A cells expressing catalytically 
impaired or inactive TDP2 were no more 
resistant to etoposide than were untransfected 
TDP2-/-/- cells or TDP2-/-/- cells transfected with 
empty vector, consistent with a requirement for 
TDP2 phosphodiesterase activity for cellular 
resistance to etoposide (Fig.4C).  In contrast to 
etoposide, TDP2-/-/- cells exhibited little or no 
hypersensitivity to MMS, a genotoxin that 
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induces DNA base damage that is repaired by 
the base excision repair pathway (Supplementary 
Fig.2A). Similarly, TDP2-/-/- cells exhibited little 
or no hypersensitivity to camptothecin (CPT) a 
Top1 poison that  induces DNA strand breaks 
with Top1-associated DNA 3’-termini 
(Supplementary Fig.2B).   
Together, these data demonstrate that 
TDP2 is a novel component of the DNA 
damage-response in vertebrate cells, and that this 
enzyme is critical for the survival of these cells 
to Top2-associated DNA strand breaks.   
 
Discussion 
 
We previously identified human TTRAP as a 5’-
tyrosyl DNA phosphodiesterase and 
consequently denoted this protein TDP2 (6). 
Here, we have extended the biochemical analysis 
of TDP2 and addressed, for the first time, the 
impact of TDP2 deletion on vertebrate cells. The 
5’-TDP activity of TDP2 was inhibited by 
vanadate suggesting that, like TDP1, cleavage of 
phosphotyrosyl bonds involves formation of a 
phosphate transition state. The activity of TDP2 
was not inhibited by the presence of excess 
BSA-tyrosine phosphate, suggesting that TDP 
activity exhibits specificity for phosphotyrosyl 
bonds present in nucleic acid substrates. TDP2 
exhibited a small preference for 5’-
phosphotyrosyl termini at blunt DSBs, compared 
to single-strand 5’-termini or internal 5’-termini 
at SSBs, consistent with a role of TDP2 in the 
repair Top2-induced DSBs in vivo. The activity 
of TDP2 on single-stranded termini may be 
physiologically relevant, however, since the 
phosphotyrosyl terminus at a Top2 DSB is 
present as a four base pair single-stranded 
overhang. Similarly, the activity of TDP2 on 5’-
phosphotyrosyl SSBs may be physiologically 
relevant, since Top2 also induces this type of 
break, due most likely to incomplete temporal 
coordination in the cleavage activity of the two 
Top2 subunits that comprise the active 
homodimer (4). In addition, Top3 also creates 
DNA breaks with 5’-phosphotyrosyl termini, 
and preferentially does so in single stranded 
DNA (15,16). 
To examine the requirement for TDP2 
for cellular response to Top2 induced DNA 
damage we generated an avian DT40 cell line in 
which all three TDP2 alleles were disrupted. 
Notably, whilst robust 5’-TDP activity was 
evident in wild-type cell extracts we detected no 
residual activity in cell extracts from TDP2-
deleted cells. This suggests that TDP2 is the 
primary, if not the only, 5’-TDP activity in 
higher eukaryotes. In addition, deletion of TDP2 
resulted in a high level of hypersensitivity to the 
Top2 poison, etoposide, and expression of 
recombinant human TDP2 complemented this 
hypersensitivity, consistent with TDP2 being a 
major mechanism for the removal of trapped 
Top2 from DNA ends. Top2-induced DSBs are 
comprised of 4 bp complementary 5’-overhangs 
in which the 5’-overhangs harbour the 
phosphotyrosyl termini. Consequently, since 
TDP2 can convert 5’-phosphotyrosyl termini 
into ligatable termini, TDP2 could provide an 
error-free mechanism for repair of Top2 DSBs in 
which the only additional DNA processing that 
is required is DNA ligation. It is likely that 
TDP2 functions in conjunction with components 
of the non homologous end joining machinery, 
with Ku and DNA ligase IV likely controlling 
events at the DSBs before and/or after TDP2 
activity. Consistent with this idea, Lig4-/- and 
Ku70-/- DT40 cells also exhibit high levels of 
sensitivity to etoposide (17).  
In contrast to etoposide, little or no 
sensitivity was observed in TDP2-/-/- DT40 cells 
to MMS or the Top1 poison camptothecin 
(CPT). The lack of sensitivity to MMS is 
consistent with this agent inducing DNA breaks 
that possess 5’-sugar phosphate (abasic) termini, 
rather than 5’-phosphotyrtosyl termini.   In 
contrast, CPT induces DNA strand breaks in 
which Top1 is linked to 3’-termini of DNA 
breaks via a phosphotyrosyl bond. Whilst TDP2 
possesses weak 3’-TDP activity it is likely that 
the primary source of such activity in cells is 
TDP1, providing a likely explanation for the 
absence of sensitivity to CPT in TDP2-deleted 
cells.  However, we have shown previously that 
TDP2 can complement the CPT sensitivity 
observed in budding yeast cells that lack both 
Tdp1 and Rad1/Rad10 nuclease-dependent 
repair mechanisms for 3’-phosphotyrosyl termini 
(6), raising the possibility that TDP2 may 
contribute to the survival of vertebrate cells in 
the absence of TDP1 and/or the Rad1/Rad10 
homologue, ERCC1/XPF.  
In summary, we describe here the first 
characterisation of a TDP2-deleted cell line, and 
demonstrate that TDP2 is the primary if not only 
source of 5’-tyrosyl DNA phosphodiesterase 
activity in vertebrate cell extracts. Moreover, we 
show that genetic deletion of TDP2 results in 
specific and high sensitivity to the Top2 ‘poison’ 
and anti-cancer agent, etoposide, identifying 
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TDP2 as a critical new component of the cellular 
defence against Top2-induced DNA damage. 
Top2 damage not only accounts for the clinical 
efficacy of Top2 poisons, an important and 
commonly used class of anti-cancer agents, but 
also accounts for some of the commonest site-
specific translocations observed in human cancer 
(4,5). Consequently, TDP2 activity may thus 
impact significantly both on the development 
and subsequent treatment of cancer, and 
inhibitors of this novel enzyme may have 
clinical utility.  
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Figure 1. The 5’-TDP activity of His-TDP2 prefers DSBs and liberates ligatable 5’-termini from 
DNA 5’-phosphotyrosine termini. (A) Purified recombinant human His-TDP2 (100nM) was incubated 
with 50nM duplex substrate harbouring a DSB with a 5’-phosphotyrosine (P-Y) terminus (top) in the 
absence or presence of the indicated concentrations of orthovanadate for 1hr at 37°C and reaction 
products separated by denaturing PAGE and detected by autoradiography.  Right, Quantification of 
the fraction (%) of total labelled oligonucleotide converted to 5’-P 19-mer product. Data are the 
average (+/- range) of two independent experiments. (B) Purified recombinant human His-TDP2 
(100nM) was incubated with duplex substrate as above in the absence or presence of the indicated 
concentrations of BSA or phosphotyrosine-BSA.  (C)  DNA substrates with a 5’-phosphotyrosine 
terminus present in single-stranded DNA (top), in a blunt-ended DNA duplex (middle), or in a nicked 
duplex (bottom), were incubated with the indicated concentrations of His-TDP2 for 1hr at 37°C and 
reaction products analysed as above.  The Middle graph is the quantification (% of total labelled 
oligonucleotide converted to 5’-P 19-mer product) of the above experiment, from three independent 
experiments mean (+/-SEM). Asterisk denotes statistically significant difference (P<0.05; t-test) 
between the indicated blunt-ended DNA duplex (‘DS-blunt’) and single-stranded DNA (‘SS-DNA’) 
data points. The bottom graph is a time course of TDP2 activity (120nM) on the blunt-ended DNA 
duplex (50nM) from a single experiment. (D) Nicked DNA duplex harbouring a 5’-phosphotyrosine 
terminus (dotted box, left) was incubated with (+) or without (-) 200nM human His-TDP2 and 50nM 
Lig3α and reaction products analysed as described above. The predicted reaction steps are depicted 
(left).  
 
Figure 2. 5’-Tyrosyl DNA phosphodiesterase activity in TDP2-/-/- cell extracts. (A) Growth curves of 
TDP2+/+/+, TDP2-/-/+ (clone H13), and TDP2-/-/- (clone 8) DT40 cells. Data are the mean +/- 1 SD of 
three independent experiments. (B) duplex substrate harbouring a DSB with a 5’-phosphotyrosine (P-
Y) terminus (top left) was incubated with whole-cell extract from TDP2+/+/+, TDP2-/-/+ and TDP2-/-/- 
DT40 cells for 20, 40 and 60 min. The percentage of substrate converted to reaction product is shown 
on the right (mean +/- SEM from 3 independent experiments). (C) Reactions conducted as in panel A 
employing TDP2+/+/+ or TDP2-/-/-  cell extracts were extended to 120 min. (D) duplex substrate 
harbouring a SSB with a 5’-phosphotyrosine (P-Y) terminus (middle) was incubated with whole-cell 
extract from TDP2+/+/+, TDP2-/-/+ and TDP2-/-/- DT40 cells for 20 min. The percentage of substrate 
converted to reaction product is shown at the bottom (mean +/- SEM from 3 independent 
experiments). (E) 5’-TDP activity was analysed as above in extracts from TDP2-/-/- cells transfected 
with empty expression vector (Vector) or with expression vector encoding either wild-type human 
TDP2 (hTDP2) or human TDP2 with a mutated catalytic domain (hTDP2D262A).  hTDP2 and actin 
expression levels were analysed by Western blotting with anti-hTDP2 and anti-actin antibodies, 
respectively (bottom). All reaction products were analysed by denaturing PAGE and 
phosphorimaging. The positions of substrate (PY) and repair product (P) are indicated.  
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Figure 3. Accumulation of TDP2-/-/- cells in sub-G1 and G2 following exposure to etoposide. Cell 
cycle profile of TDP2+/+/+ and TDP2-/-/-  (clone 8) DT40 cells that were cultured for 24 or 48 hr in the 
presence or absence of 40nM etoposide, as indicated. The accumulation of cells in G2/M or sub-G1 in 
response to etoposide treatment is indicated by large and small arrow heads, respectively. The fraction 
of cells with sub-G1, G1, S phase, and G2 DNA content is expressed as a % of the total cells in each 
sample and is tabulated.  
 
Figure 4. Cellular hypersensitivity of TDP2-/-/- cells to the Top2 poison, etoposide. (A)  Clonogenic 
survival of TDP2+/+/+, TDP2-/-/+, and TDP2-/-/- (clone 8) cells cultured in the indicated concentrations of 
etoposide. (B)  Clonogenic survival of TDP2+/+/+and TDP2-/-/- (clone 93) cells cultured as above. (C) 
Clonogenic survival of TDP2+/+/+ cells, TDP2-/-/- cells (clone 8), and pooled populations of TDP2-/-/- 
(clone 8)  transfectants harbouring empty expression vector (‘vector’) or expression vector encoding 
either wild-type human TDP2 (‘TDP2’) or TDP2 with a mutated catalyric domain ( ‘TDP2 D262A’). 
Data are the mean +/-SEM of three independent experiments. 
 
Supplementary Figure 1. Generation of TDP2-/-/- mutant clones. (A) Schematic representation of 
targeted disruption of the chicken TDP2-/-/- gene. The chicken TDP2 locus is illustrated as a solid black 
line at the top, with exons indicated as solid black boxes. The integration position of the targeting 
construct employed for disruption of the 1st TDP2 allele, containing TDP2 genomic sequences (red 
lines) separated by a puromycin selectable marker (red box), is shown. The targeting constructs 
employed for disruption of the 2nd and 3rd TDP2 alleles, harbouring the selectable markers HisD and 
Bsr, are shown in green and blue, respectively. The predicted sizes of EcoRV/XhoI restriction 
fragments for cells containing zero (wild-type), one, two, or three disrupted TDP2 alleles are indicated 
by black arrows. (B) Southern blot analysis of wild-type DT40 cells (+/+/+) and single clones 
harbouring one (+/+/-), two (-/-/+; clone H13), or three (-/-/-; clone 8) disrupted alleles. EcoRV/XhoI-
digested genomic DNA was hybridized with the N probe depicted above. 
 
 Supplemental Figure 2.  Normal sensitivity of TDP2-/-/- cells to DNA alkylating agent MMS and 
the Top1 poison, camptothecin. Clonogenic survival of TDP2+/+/+, TDP2-/-/+, and TDP2-/-/- (clone 8) 
cells cultured in the indicated concentrations of MMS (A) or CPT (B).  
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